Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and optimisation trial will enrol...

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF...

With commitments from international pension funds, banks, fund-of-funds, endowments and family offices, Gilde Healthcare realizes an initial close at €250 million Expansion into Climate Solutions builds on Gilde Healthcare’s track record in impactful investing and...